(Press-News.org) Health systems worldwide are increasingly negotiating secret price rebates from pharmaceutical companies and Canadians risk losing out on the deal.
"The pricing of medicines is now a game of negotiation, similar to buying a car at a dealership," says Steve Morgan, an expert in health policy at the University of British Columbia. "There's a list price equivalent to a manufacturer's suggested retail price; and then there's secret deals that everyone negotiates from there."
In a study published today in the April issue of the journal Health Affairs, researchers interviewed policymakers from nine developed countries and analyzed practices for securing confidential manufacturers' rebates.
They confirmed that almost all countries are now routinely negotiating rebates from drug companies as a condition of coverage under their health care systems. Manufacturers are promoting these rebates because the associated confidentiality clause ensures deals struck in one country don't set precedent in others.
Countries with multi-payer health care systems, including the U.S. and Canada, have less bargaining power in these negotiations. Meanwhile, despite its relatively small population, New Zealand leverages its universal public drug plan to negotiate rebates for all covered medicines.
After "Obama Care" expands health insurance to all Americans in 2014, Canada may be the country least capable of effectively managing this new pricing regime, says Morgan, an associate professor in the School of Population and Public Health.
Canada is the only country in the world with universal coverage for medical and hospital care but not for prescription drugs. Individual provinces and insurers negotiate drug prices independently – although some provinces are working cooperatively to lower prices.
"The Canadian system is fundamentally flawed," says Morgan. "Ironically, the smaller provinces and uninsured Canadians will end up paying the highest out-of-pocket costs for their medicines."
BACKGROUND
About the study
Researchers conducted interviews with pharmaceutical policy makers from Australia, Austria, Canada, Germany, Italy, the Netherlands, New Zealand, the United Kingdom, and the United States. Among these countries, Canada has the second highest level of spending on medicines and the second highest prices for top-selling drugs, behind the United States.
The researchers then held a face-to-face meeting with policy makers from all the participating countries to discuss lessons learned and to refine recommendations regarding best practices. Based on these discussions, Morgan and his colleagues suggest that policy makers follow three principles in developing a new pricing strategy: pragmatism, discipline and transparency.
Pragmatism: Most countries that have tried performance-based rebate schemes found them difficult to enforce. Governments should strive to keep pharmaceutical rebates relatively simple.
Discipline: Well-designed decision-making systems are required to ensure that drug plans don't lose control in negotiations with manufacturers.
Transparency: Process transparency is essential because the negotiated price will always remain secret under the new pricing paradigm. Currently, most provinces negotiate rebates from drug manufacturers but few disclose information about the existence, nature, or scale of those rebates.
###
CONTACT
Prof. Steve Morgan
UBC School of Population and Public Health
Twitter: @SteveUBC
Katherine Came
UBC School of Population and Public Health (Communications)
Tel: 604-822-0530
E-mail: katherine.came@ubc.ca END
Canada loses out on drug pricing: UBC study
2013-04-09
ELSE PRESS RELEASES FROM THIS DATE:
Strict school meal standards associated with improved weight status among students
2013-04-09
A study suggests that states with stricter school meal nutrition standards were associated with better weight status among students who received free or reduced-price lunches compared with students who did not eat school lunches, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.
The National School Lunch Program (NSLP) was started in 1946 to improve student nutrition by providing school lunches according to standards sets by the U.S. Department of Agriculture (USDA). However, the program has faced criticism that the lunches did ...
Pre-pregnancy body fat, in-pregnancy weight gain, and gestational diabetes combine to increase risk of high birthweight babies to differing degrees in white, black, Hispanic, and Asian women
2013-04-09
A new study shows that a woman's pre-pregnancy body fat (adiposity), in-pregnancy weight gain, and presence of gestational diabetes mellitus (GDM) can all combine to steeply increase the risk of giving birth to large-for-gestational age (LGA) babies to different degrees in white non-Hispanic, black non-Hispanic, White Hispanic, and Asian women, with the highest combined risk being in White non-Hispanic women. The research is published in the journal Diabetologia (the journal of the European Association for the Study of Diabetes) and is led by Dr Katherine Bowers and Dr ...
Environmental change triggers rapid evolution
2013-04-09
A University of Leeds-led study, published in the journal Ecology Letters, overturns the common assumption that evolution only occurs gradually over hundreds or thousands of years.
Instead, researchers found significant genetically transmitted changes in laboratory populations of soil mites in just 15 generations, leading to a doubling of the age at which the mites reached adulthood and large changes in population size. The results have important implications in areas such as disease and pest control, conservation and fisheries management because they demonstrate that ...
Adding intestinal enzyme to diets of mice appears to prevent, treat metabolic syndrome
2013-04-09
Feeding an intestinal enzyme to mice kept on a high-fat diet appears to prevent the development of metabolic syndrome – a group of symptoms associated with type 2 diabetes, cardiovascular disease and fatty liver – and to reduce symptoms in mice that already had the condition. In their report published online in PNAS Early Edition, Massachusetts General Hospital (MGH) investigators describe how dietary supplementation with intestinal alkaline phosphatase (IAP) reduced the inflammation believed to underlie metabolic syndrome by blocking a toxic molecule found on the surface ...
Nearly half of breast cancer patients at risk of having BRCA mutations not sent for genetic testing
2013-04-09
WASHINGTON, DC -- Only 53 percent of newly diagnosed breast cancer patients who were at high risk of carrying a BRCA 1 or BRCA 2 mutation – based on age, diagnosis, and family history of breast or ovarian cancer – reported that their doctors urged them to be tested for the genes, according to a research team from the Perelman School of Medicine at the University of Pennsylvania.
The findings, which will be presented during the American Association for Cancer Research Annual Meeting 2013 (Presentation #1358), were drawn from surveys completed by 2,258 women between 18 ...
Adding cetuximab to chemotherapy enables select patients with advanced colorectal cancer and liver metastasis to undergo surgery, extending survival by several months
2013-04-09
In this News Digest:
Summary of a study being published online April 8, 2013 in the Journal of Clinical Oncology, reports that adding cetuximab (Erbitux) to chemotherapy enabled previously inoperable patients to undergo surgery, tripling the rates of successful surgery for liver metastasis.
The combination of cetuximab and chemotherapy extended median overall survival for this population of patients by 10 months compared with chemotherapy alone.
Quote for attribution to Neal Meropol, MD, American Society of Clinical Oncology Cancer Communications Committee member ...
Month of birth impacts on immune system development
2013-04-09
Newborn babies' immune system development and levels of vitamin D have been found to vary according to their month of birth, according to new research.
The research, from scientists at Queen Mary, University of London and the University of Oxford, provides a potential biological basis as to why an individual's risk of developing the neurological condition multiple sclerosis (MS) is influenced by their month of birth. It also supports the need for further research into the potential benefits of vitamin D supplementation during pregnancy.
Around 100,000 people in the ...
Study finds key to calling back-up help when tumor-fighter p53 goes down
2013-04-09
WASHINGTON, D.C. – Tumor suppression, the family business of the sibling genes p53, p63 and p73, is undermined from within by the split personalities of p63 and p73, which each produce protein forms that not only block the work of the other two genes but also shut down its own cancer-stifling fraternal twin.
In a presentation at the AACR Annual Meeting 2013, scientists from The University of Texas MD Anderson Cancer Center demonstrate that tumor suppression can be restored in mice that lack p53 by knocking out the ∆N isoforms of p63 and p73 that interfere with tumor ...
AACR news: XL-184 (Cabozantinib) goes 12-for-12 in colorectal cancer explants
2013-04-09
The novel c-MET and VEGFR2 inhibitor, XL-184 (Cabozantinib), resulted in a significant decrease in tumor growth in 12 out of 12 colorectal cancer (CRC) patient-derived explants, with 8 of the explants exhibiting stable disease. The results of this preclinical work are presented at the AACR Annual Meeting 2013.
"With molecularly targeted agents, we typically see 3 or 4 CRC explant models with a significant decrease in tumor growth. Here we have a drug that was active in every explant we tested. It's really exciting," says John Arcaroli, PhD, investigator at the University ...
AACR news: Autophagy-addicted breast cancers killed by anti-malaria drug, chloroquine
2013-04-09
The process of autophagy cleans cells – they wrap up the bad stuff and then dispose of it. And so it stands to reason that inhibiting autophagy would make cancer cells less able to cleanse themselves of chemotherapy and so more susceptible to the drugs. That's what the traditional anti-malaria drug, chloroquine, does – it inhibits autophagy. Existing clinical trials are testing chloroquine/chemotherapy combinations against breast cancer.
Research presented at the AACR Annual Meeting 2013 shows that some breast cancer subtypes depend on autophagy more than others – and ...